Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ATS Corp T.ATS

Alternate Symbol(s):  ATS

ATS Corporation is a Canada-based automation solutions provider. The Company uses its knowledge base and global capabilities in custom automation, repeat automation, automation products and value-added services, including pre-automation and after-sales services, to address the sophisticated manufacturing automation systems and service needs of multinational customers in markets, such as life sciences, food and beverage, transportation, consumer products, and energy. It engages with customers on both greenfield programs, such as equipping new factories, and brownfield programs, including capacity expansions, production relocations, equipment upgrades, software upgrades, efficiency improvements and factory optimizations. It offers post-automation services. It also offers artificial intelligence (AI) and machine learning (ML)-based tools for industrial production. The Company also designs and manufactures automated water purification solutions for biomedical and life science applications.


TSX:ATS - Post by User

<< Previous
Bullboard Posts
Next >>
Post by retiredcfon May 21, 2024 8:29am
69 Views
Post# 36049570

RBC 2

RBC 2Their upside scenario target is $67.00. GLTA

May 20, 2024

Outperform

TSX: ATS; CAD 47.51; NYSE: ATS

Price Target CAD 60.00 ↓ 65.00

ATS Corporation Good underlying growth

Our view: ATS reported Q4/F24 results ahead of Street expectations. Despite some headwinds in the Transportation/EV business, ATS' other end-markets continue to trend well. Looking ahead to F2025, we think the company will deliver EBIT growth (reflecting margin expansion), which we view favourably considering the uncertainty in Transportation. Revising PT -$5 to $60; reiterate OP.

Key points:

Thoughts exiting Q4/F24 – Overall, ATS reported Q4/F24 results that were ahead of Street expectations (see inside for details). The Transportation end-market was in focus yet again this quarter as a key EV customer for ATS cancelled $50MM of work out of $200MM of backlog that had previously been "on hold" (remaining $150MM is still on hold but remains in ATS' backlog). While this created some noise with respect to the backlog conversion guide for Q1/F25 (36%-40%, below the historical ~mid-40% range), our focus is on the strong book-to-bill that ATS has been able to deliver in its other end-markets. Specifically, LTM book-to-bill was 1.13x, 1.06x, and 1.4x for Life Sciences, Food & Beverage, and Energy, respectively. Looking ahead, these metrics point to an outlook for strong organic revenue growth across these end-markets in F2025, which we believe should offset lower-than-expected Transportation revenue next year (a restart in the above-noted $150MM of paused backlog would be upside to our estimates, though management emphasized the timing of a restart remains uncertain at this stage). Also of note, ATS does not expect any margin headwinds heading into F2025 (EBIT margin in F2024 was 13.1% for reference), which we view favourably against the backdrop of the above- noted Transportation disruptions.

Life Sciences/GLP-1 update – We estimate Life Sciences Net Bookings reached $371.2MM in FQ4 (+19.4% YoY), reflecting continue strong demand across ATS' focus end-markets (namely pharmaceuticals and medical devices). Additionally, ATS continues to position the business to capitalize on the emerging GLP-1 tailwind. For perspective, GLP-1 drugs were a ~LSD% contributor to ATS' F2024 revenue, while in recent quarters GLP-1/autoinjectors have represented ~HSD%-LDD% of overall Bookings. We believe this points to the overall revenue contribution from GLP-1 growing through F2025, and management estimates that this product line will move toward ~HSD% of overall revenue over the coming years (there could be upside to this estimate as GLP-1s get approved for new use cases).

Balance Sheet in good shape – FQ4 leverage stood at 2.4x, while on the call management reiterated that M&A remains the focus from a capital allocation standpoint (recent Paxiom deal adds a high-margin platform). Looking ahead, we think organic investments/innovation will represent another attractive use of capital for the company, while the NCIB will be used opportunistically, in our view


<< Previous
Bullboard Posts
Next >>